Risk-Stratified Treatment in Chronic Lymphocytic Leukemia
November 6, 2015
Learning Objectives
- Assess risk and monitor response to treatment by combining classic leukemia staging methods with novel pathology biomarkers and prognostic factors
- Discuss strategies for managing side effects of novel therapies, as well as preventing infections
- Describe best practices for optimizing selection and sequencing of treatments in the upfront and relapsed/refractory settings
- Explain the role of the Advanced Practitioner as a member of the collaborative practice team in caring for patients with CLL through the trajectory of their illness
United States
Amy Goodrich, MSN, CRNP
Deborah M. Stephens, DO
Available Credit
- 1.00 AANP
- 0.67 Pharmacology
- 1.00 ACPE
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Attendance
- 1.00 ANCC